10.6084/m9.figshare.c.3871963_D1.v1 Faye Norby Faye Norby Lindsay Bengtson Lindsay Bengtson Pamela Lutsey Pamela Lutsey Lin Chen Lin Chen Richard MacLehose Richard MacLehose Alanna Chamberlain Alanna Chamberlain Ian Rapson Ian Rapson Alvaro Alonso Alvaro Alonso Additional file 1: Supplemental Materials. of Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation Springer Nature 2017 Non-valvular atrial fibrillation Stroke Warfarin Dabigatran Rivaroxaban 2017-09-06 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Supplemental_Materials_of_Comparative_effectiveness_of_rivaroxaban_versus_warfarin_or_dabigatran_for_the_treatment_of_patients_with_non-valvular_atrial_fibrillation/5378707 Table S1. Characteristics of atrial fibrillation patients by anticoagulant use prior to final matching based on high-dimensional propensity score, MarketScan, 2010–2014. Table S2. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users (categorized by initial dose) to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S3. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing patients who switched to rivaroxaban (categorized by initial dose) from warfarin to warfarin-only users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S4. Adjusted hazard ratios (95% confidence intervals) comparing new rivaroxaban users (categorized by initial dose) to new dabigatran users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S5. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Restricted to 36,623 patients with at least 180 days of enrolment before first oral anticoagulation prescription. Table S6. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Restricted to 68,927 patients with an enrolment date later than January 1st, 2011. Table S7. ICD-9-CM codes for outcomes. Table S8. ICD-9-CM codes used to define comorbidities. Figure S1. High-dimensional propensity score distribution by oral anticoagulant status for the outcome of stroke. These are the distributions prior to final matching based on high-dimensional propensity score. (DOCX 356 kb)